Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis.

Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis.
复制标题

DOI:
10.1183/16000617.0100-2023
复制
发表时间:
2023-09-30
期刊:
European respiratory review : an official journal of the European Respiratory Society
影响因子:
--
通讯作者:
Krymskaya VP
Krymskaya VP
中科院分区:
其他
文献类型:
--
作者:
Evans JF;McCormack FX;Sonenberg N;Krymskaya VP

文献摘要

参考文献

相似文献

淋巴管肌瘤病(LAM)是一种女性囊性肺部疾病,由结节性硬化症复合体(TSC)基因突变所致,这些基因可抑制哺乳动物雷帕霉素靶蛋白复合体1(mTORC1)通路。mTORC1的激活可增强众多合成代谢相关的细胞功能,主要是通过刺激核糖体蛋白S6激酶(S6K1)/核糖体蛋白S6(S6)以及真核起始因子4E结合蛋白1(4E - BP1)/真核翻译起始因子4E(eIF4E)来激活信使核糖核酸(mRNA)的翻译过程。雷帕霉素(西罗莫司)作为mTORC1的变构抑制剂,可稳定许多但并非所有LAM患者的肺功能,且一旦停药,疾病就会继续进展。在临床可耐受浓度下,雷帕霉素能有效抑制核糖体S6K1/S6翻译、核糖体生物合成及延伸轴,但对翻译4E - BP1/eIF4E起始轴无抑制作用。在这篇小型综述中,我们提出,抑制mTORC1驱动的翻译起始过程,是针对LAM、TSC及其他mTORC1驱动疾病一种明显却未得到充分重视的治疗策略。 抑制对雷帕霉素不敏感的mRNA翻译起始过程,是淋巴管肌瘤病中一种未得到充分重视的治疗策略。https://bit.ly/3Oj5Fze
Lymphangioleiomyomatosis (LAM) is a cystic lung disease of women resulting from mutations in tuberous sclerosis complex (TSC) genes that suppress the mammalian target of rapamycin complex 1 (mTORC1) pathway. mTORC1 activation enhances a plethora of anabolic cellular functions, mainly via the activation of mRNA translation through stimulation of ribosomal protein S6 kinase (S6K1)/ribosomal protein S6 (S6) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)/eukaryotic translation initiation factor 4E (eIF4E). Rapamycin (sirolimus), an allosteric inhibitor of mTORC1, stabilises lung function in many but not all LAM patients and, upon cessation of the drug, disease progression resumes. At clinically tolerable concentrations, rapamycin potently inhibits the ribosomal S6K1/S6 translation ribosome biogenesis and elongation axis, but not the translation 4E-BP1/eIF4E initiation axis. In this mini-review, we propose that inhibition of mTORC1-driven translation initiation is an obvious but underappreciated therapeutic strategy in LAM, TSC and other mTORC1-driven diseases. Inhibition of rapamycin-insensitive mRNA translation initiation is an underappreciated therapeutic strategy in lymphangioleiomyomatosis. https://bit.ly/3Oj5Fze
DOI: 10.1038/onc.2013.92
发表时间: 2014-03-20
期刊: Oncogene
影响因子: 8
作者:
通讯作者: --
DOI: 10.3389/fonc.2021.766298
发表时间: 2021
影响因子: 4.7
作者:
Gerson-Gurwitz A;Young NP;Goel VK;Eam B;Stumpf CR;Chen J;Fish S;Barrera M;Sung E;Staunton J;Chiang GG;Webster KR;Thompson PA
通讯作者: Thompson PA
DOI: 10.1038/s41589-021-00813-7
发表时间: 2021-10
影响因子: 14.8
作者:
Lee, Bianca J.;Boyer, Jacob A.;Burnett, G. Leslie;Thottumkara, Arun P.;Tibrewal, Nidhi;Wilson, Stacy L.;Hsieh, Tientien;Marquez, Abby;Lorenzana, Edward G.;Evans, James W.;Hulea, Laura;Kiss, Gert;Liu, Hui;Lee, Dong;Larsson, Ola;McLaughlan, Shannon;Topisirovic, Ivan;Wang, Zhengping;Wang, Zhican;Zhao, Yongyuan;Wildes, David;Aggen, James B.;Singh, Mallika;Gill, Adrian L.;Smith, Jacqueline A. M.;Rosen, Neal
通讯作者: Rosen, Neal
DOI: 10.1038/s41416-020-01205-9
发表时间: 2021-03
影响因子: 8.8
作者:
Herzog LO;Walters B;Buono R;Lee JS;Mallya S;Fung A;Chiu H;Nguyen N;Li B;Pinkerton AB;Jackson MR;Schneider RJ;Ronai ZA;Fruman DA
通讯作者: Fruman DA
DOI: 10.1158/1535-7163.mct-14-1052
发表时间: 2015-06-01
影响因子: 5.7
作者:
Mortensen, Deborah S.;Fultz, Kimberly E.;Raymon, Heather K.
通讯作者: Raymon, Heather K.